Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer.

@article{Fraenkel2002InductionOM,
  title={Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer.},
  author={Paula G. Fraenkel and Seward B. Rutkove and Jean K. Matheson and Mary E. Fowkes and M. Elizabeth Cannon and M F Patti and Michael B. Atkins and Jared A. Gollob},
  journal={Journal of immunotherapy},
  year={2002},
  volume={25 4},
  pages={373-8}
}
Interleukin-2 is an effective agent against renal cell carcinoma and melanoma, but it has been associated with autoimmune sequelae such as hypothyroidism and vitiligo. A 64-year-old man with non-insulin-dependent diabetes and metastatic renal cell carcinoma developed insulin-dependent diabetes after his first cycle of therapy with high-dose (HD) interleukin-2. After additional therapy with interleukin-2, the patient developed generalized myasthenia gravis (MG) and polymyositis, both of which… CONTINUE READING